# A Phase 2b Diabetic Kidney Disease Study

> **NCT04170543** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 609 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** MEDI3506
- **DRUG:** Placebo
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT04170543
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-18
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 609 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170543, "A Phase 2b Diabetic Kidney Disease Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04170543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*